The biopharmaceutical company reported robust Q1 2025 results, including $9.0 million in net product revenue, and obtained UK marketing authorization for its lead product AUCATZYL.
The biotechnology company reports positive interim results from a Phase II trial of its gene therapy for a rare inherited retinal disease.
The targeted oncology therapeutics company Mosaic Therapeutics has in-licensed two clinical-stage assets from Astex Pharmaceuticals, accelerating its development pipeline.
The biopharmaceutical company reports full year 2024 financial results, including increased cash position and progress on the commercial launch of its lead product AUCATZYL.
The asset management firm has announced a change in major shareholding, with the Wellcome Trust increasing its stake in the company.
The life science investor reports progress in its portfolio, with key milestones delivered by several companies. However, negative returns and a widening discount to NAV continue to weigh on performance.
The life sciences company will be liquidated, returning capital to shareholders, after failing to achieve its strategic goals.
The biotechnology company announces positive data from a Phase I/II trial of its gene therapy for Gaucher disease, showing improvements in key disease markers and a favorable safety profile.
The biopharmaceutical company has sold certain technology assets to AstraZeneca for $12 million, as part of a strategic review.
Positive data for rare cancer drug from Syncona's portfolio company, setting the stage for further development.